Sites of disease as predictors of outcome in metastatic renal cell carcinoma patients treated with first-line sunitinib or sorafenib

Sites of disease as predictors of outcome in metastatic renal cell carcinoma patients treated with first-line sunitinib or sorafenib

Background: This study investigated whether the effectiveness of first-line tyrosine-kinase inhibitors was associated with sites of disease in patients with metastatic renal cell carcinoma (mRCC). Methods: A retrospective cohort of consecutive mRCC patients receiving first-line sorafenib (SO) or sun...

Full description

Bibliographic Details
Main Authors: Paolo Grassi, Elena Verzoni, Luca Porcu, Roberto Iacovelli, Filippo de Braud, Giuseppe Procopio
Format: Article
Language:English
Published: SAGE Publishing 2015-04-01
Series:Therapeutic Advances in Urology
Online Access:https://doi.org/10.1177/1756287215571809

Similar Items

Similar Items